Clinical trials: Relapsed ALL, Adult
Non-Hodgkins Lymphoma, Hodgkins Lymphoma
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
The administration of allogeneic third party derived LMP specific-CTLs (special peripheral blood cells from another person) that are made specific to fight EBV infection) in Children, Adolescents and Young Adults (CAYA) with…
- Conditions
- Non-Hodgkins Lymphoma, Hodgkins Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT02057445
- Testing
- EBV CTL's, Peripheral Blood Donor
- Where
- 2 sites in United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- New York Medical College
Glioblastomas, Sarcoma
Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children and Young Adults With High Grade or High-Risk Cancer and Their Caregivers
Background: People cope with cancer in different ways. Mindfulness means focusing on the present moment with an open mind. Researchers want to see if this can help children and young adults with a high-grade high-risk cancer with…
- Conditions
- Glioblastomas, Sarcoma, Astrocytoma, Brain Cancer
- Trial name
- NCT03538587
- Testing
- Enhanced Mindfulness Intervention, Psychoeducation
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Depression, Depressive Disorder, Major
Decentering and Relapse/Recurrence in MBCT for Depression in Adults
Objective: "Decentering" is defined as the ability to observe one's thoughts and feelings as temporary, objective events in the mind, and is increasingly regarded as a candidate mechanism in mindfulness-based interventions.
- Conditions
- Depression, Depressive Disorder, Major, Depression in Remission
- Trial name
- NCT05111665
- Testing
- Mindfulness-based Cognitive Therapy (MBCT), Relaxation Group Therapy (RGT), Treatment as usual (TAU)
- Where
- Canada
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT.
- Conditions
- Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
- Trial name
- NCT05595447
- Testing
- Brentuximab Vedotin 50 MG [Adcetris]
- Where
- Mexico
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hospital Regional de Alta Especialidad del Bajio
Hodgkin Lymphoma
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
Patients with relapsed or refractory Hodgkin Lymphoma who are CD30+ will receive a standard of care reduced intensity regimen and an allogeneic stem cell transplant (from another person, related or unrelated).
- Trial name
- NCT02098512
- Testing
- Brentuximab Vedotin, Allogeneic Stem Cell Transplantation, Reduced Intensity Conditioning
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- New York Medical College
Depressive Disorder, Anxiety Disorders
StayFine: Personalised Relapse Prevention of Anxiety and Mood Disorders in Youths
The current study examines the effectiveness of the StayFine app for relapse prevention of anxiety or depressive disorders in youth using a randomized controlled trial.
- Trial name
- StayFine (NCT05551468)
- Testing
- StayFine guided app-based personalised intervention modules, StayFine app-based monitoring
- Where
- Netherlands
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- Ggz Oost Brabant
Gut Microbiome, Gastrointestinal Microbiome
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder
- Trial name
- NCT04031469
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
Lymphoma, Leukemia
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
Background: CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells.
- Trial name
- NCT05237986
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)